TIDMNSCI
NetScientific PLC
10 January 2022
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy
London, UK - 10 January 2022 - NetScientific plc (AIM: NSCI),
the international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB),
announced that it has been granted U.S. Patent Application No.
15,724,818 titled "Novel HPV16 Non HLA-Restricted T-cell Vaccines,
Composition and Methods of Use Thereof" by the United States Patent
and Trademark Office (USPTO).
The newly issued patent covers the PDS0101 immunotherapy which
consists of a combination of the Versamune technology platform with
a unique mixture of short protein fragments derived from the
cancer-causing virus, HPV16. The composition promotes the induction
of killer (CD8+) T-cells by the immune system that recognize, and
attack cancers caused by infection with HPV16 irrespective of the
patients' genetic makeup.
HPV16 is the most oncogenic or cancer-causing type of HPV, and
is by far the most prevalent in patients with advanced
HPV-associated cancers, including anal, cervical, head and neck,
penile, vaginal and vulvar cancers. More than 40,500 patients are
diagnosed with HPV16-associated cancers each year according to the
International Journal of Cancer. Some of these cancers have been
reported to be increasing in incidence over the last few years.
Dr. Frank Bedu-Addo, President and Chief Executive Officer of
PDS Biotech, said: "We remain excited about the promising early
efficacy and safety data from our ongoing Phase 2 clinical trials.
The early clinical data coupled with the recent grant of the
PDS0101 patent that runs into late 2037 puts PDS Biotech in a
strong position to progress commercialization of the product to
address a significant unmet need for more effective treatment of
advanced HPV-associated cancers".
Ilian Iliev, CEO of NetScientific, commented: "A strong,
effective and fit-for-purpose patent portfolio is key to effective
commercialisation in life sciences, and a key element in
NetScientific's portfolio management and investment selection
strategy. PDS' growing patent portfolio positions the company well
for success, as the company continues to progress its clinical
trials."
The full text of the announcement from PDS Biotechnology is
reproduced below and is available online here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/118-2022-news/584-iotechrantedatentforitsovel16mmunotherap20220110
###
FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company's proprietary Versamune(R) T-cell activating
technology, today announced that it has been granted U.S. Patent
Application No. 15,724,818 titled "Novel HPV16 Non HLA-Restricted
T-cell Vaccines, Composition and Methods of Use Thereof" by the
United States Patent and Trademark Office (USPTO).
The newly issued patent covers the PDS0101 immunotherapy which
consists of a combination of the Versamune technology platform with
a unique mixture of short protein fragments derived from the
cancer-causing virus, HPV16. The composition promotes the induction
of killer (CD8+) T-cells by the immune system that recognize, and
attack cancers caused by infection with HPV16 irrespective of the
patients' genetic makeup.
HPV16 is the most oncogenic or cancer-causing type of HPV, and
is by far the most prevalent in patients with advanced
HPV-associated cancers, including anal, cervical, head and neck,
penile, vaginal and vulvar cancers. More than 40,500 patients are
diagnosed with HPV16-associated cancers each year according to the
International Journal of Cancer. Some of these cancers have been
reported to be increasing in incidence over the last few years.
"We remain excited about the promising early efficacy and safety
data from our ongoing Phase 2 clinical trials. The early clinical
data coupled with the recent grant of the PDS0101 patent that runs
into late 2037 puts PDS Biotech in a strong position to progress
commercialization of the product to address a significant unmet
need for more effective treatment of advanced HPV-associated
cancers," stated Frank Bedu-Addo, Chief Executive Officer of PDS
Biotech.
In partnership with Merck & Co., PDS Biotech is evaluating a
combination of PDS0101 and KEYTRUDA(R) in a Phase 2 study
(NCT04260126) in first-line treatment of recurrent or metastatic
head and neck cancer, and also in second-line treatment of
recurrent or metastatic head and neck cancer in patients who have
failed prior checkpoint inhibitor therapy. PDS Biotech is also
conducting a Phase 2 clinical study in both second- and third-line
treatment of multiple advanced HPV-associated cancers with the
National Cancer Institute (NCI). A third Phase 2 clinical trial in
first-line treatment of locally advanced cervical cancer is being
performed with The University of Texas, MD Anderson Cancer
Center.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of cancer immunotherapies based on the Company's
proprietary Versamune(R) T-cell activating technology platform. Our
Versamune(R) -based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune(R) and disease-specific antigens, designed to train
the immune system to better recognize diseased cells and
effectively attack and destroy them. The Company's pipeline
products address various cancers including HPV16-associated cancers
(anal, cervical, head and neck) and breast, colon, lung, prostate
and ovarian cancers. To learn more, please visit www.pdsbiotech.com
or follow us on Twitter at @PDSBiotech.
Forward Looking Statements
This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States
Securities Exchange Act of 1934, as amended, and Section 27A of the
United States Securities Act of 1933, as amended) concerning PDS
Biotechnology Corporation (the "Company") and other matters. These
statements may discuss goals, intentions and expectations as to
future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company's
management, as well as assumptions made by, and information
currently available to, management. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect,"
"anticipate," "plan," "likely," "believe," "estimate," "project,"
"intend," "forecast," "guidance", "outlook" and other similar
expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the Company's ability to protect its
intellectual property rights; the Company's anticipated capital
requirements, including the Company's anticipated cash runway and
the Company's current expectations regarding its plans for future
equity financings; the Company's dependence on additional financing
to fund its operations and complete the development and
commercialization of its product candidates, and the risks that
raising such additional capital may restrict the Company's
operations or require the Company to relinquish rights to the
Company's technologies or product candidates; the Company's limited
operating history in the Company's current line of business, which
makes it difficult to evaluate the Company's prospects, the
Company's business plan or the likelihood of the Company's
successful implementation of such business plan; the timing for the
Company or its partners to initiate the planned clinical trials for
PDS0101, PDS0203 and other Versamune(R) based products; the future
success of such trials; the successful implementation of the
Company's research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and
other Versamune(R) based products and the Company's interpretation
of the results and findings of such programs and collaborations and
whether such results are sufficient to support the future success
of the Company's product candidates; the success, timing and cost
of the Company's ongoing clinical trials and anticipated clinical
trials for the Company's current product candidates, including
statements regarding the timing of initiation, pace of enrollment
and completion of the trials (including our ability to fully fund
our disclosed clinical trials, which assumes no material changes to
our currently projected expenses), futility analyses, presentations
at conferences and data reported in an abstract, and receipt of
interim results, which are not necessarily indicative of the final
results of the Company's ongoing clinical trials; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; the acceptance by the market of the
Company's product candidates, if approved; the timing of and the
Company's ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company's product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company's control,
including unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19. The
foregoing review of important factors that could cause actual
events to differ from expectations should not be construed as
exhaustive and should be read in conjunction with statements that
are included herein and elsewhere, including the risk factors
included in the Company's annual and periodic reports filed with
the SEC. The forward-looking statements are made only as of the
date of this press release and, except as required by applicable
law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
###
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR +44 (0)20 7933 8780 or netscientific@walbrookpr.com
Nick Rome / Nicholas Johnson / Paul 07748 325 236 / 07884 664 686 / 07980
McManus 541 893
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: netscientific.net ).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAURASRUUUAAAR
(END) Dow Jones Newswires
January 10, 2022 09:20 ET (14:20 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024